Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer

NCT03562871 is registered in ClinicalTrials.gov with IO Biotech as lead sponsor.

NCT NCT03562871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03562871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer
Lead sponsor
IO Biotech
Phase
Phase 1/2
Overall status
Completed
Start date
August 22, 2018
Completion date
April 12, 2022
Enrollment
109 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc